



HAL
open science

Exploring the genetics of lithium response in bipolar disorders

Marisol Herrera-Rivero, Mazda Adli, Kazufumi Akiyama, Nirmala Akula, Azmeraw Amare, Raffaella Arda, Bárbara Arias, Jean-Michel Aubry, Lena Backlund, Frank Bellivier, et al.

► **To cite this version:**

Marisol Herrera-Rivero, Mazda Adli, Kazufumi Akiyama, Nirmala Akula, Azmeraw Amare, et al.. Exploring the genetics of lithium response in bipolar disorders. *International Journal of Bipolar Disorders*, 2024, 12 (1), pp.20. 10.1186/s40345-024-00341-y . hal-04778490

HAL Id: hal-04778490

<https://hal.science/hal-04778490v1>

Submitted on 6 Jan 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access



Exploring the genetics of lithium response in bipolar disorders

Marisol Herrera-Rivero¹, Mazda Adli^{2,3}, Kazufumi Akiyama⁴, Nirmala Akula⁵, Azmeraw T. Amare⁶, Raffaella Ardu⁷, Bárbara Arias⁸, Jean-Michel Aubry^{9,10}, Lena Backlund¹¹, Frank Bellivier¹², Antonio Benabarre¹³, Susanne Bengesser¹⁴, Abesh Kumar Bhattacharjee¹⁵, Joanna M. Biernacka^{16,17}, Armin Birner¹⁴, Micah Cearn⁶, Pablo Cervantes¹⁸, Hsi-Chung Chen¹⁹, Caterina Chillotti⁷, Sven Cichon^{20,21,22}, Scott R. Clark⁶, Francesc Colom^{23,24}, Cristiana Cruceanu²⁵, Piotr M. Czerski²⁶, Nina Dalkner¹⁴, Franziska Degenhardt²⁷, Maria Del Zompo²⁸, J. Raymond DePaulo²⁹, Bruno Etain¹², Peter Falkai³⁰, Ewa Ferencztajn-Rochowiak³¹, Andreas J. Forstner^{22,27}, Josef Frank³², Louise Frisén³³, Mark A. Frye¹⁷, Janice M. Fullerton³⁴, Carla Gallo³⁵, Sébastien Gard³⁶, Julie S. Garnham³⁷, Fernando S. Goes²⁹, Maria Grigoriou-Serbanescu³⁸, Paul Grof³⁹, Ryota Hashimoto⁴⁰, Roland Hasler⁹, Joanna Hauser²⁶, Urs Heilbronner⁴¹, Stefan Herms^{20,27}, Per Hoffmann^{20,27}, Liping Hou⁵, Yi-Hsiang Hsu⁴², Stephane Jamain⁴³, Esther Jiménez⁴⁴, Jean-Pierre Kahn⁴⁵, Layla Kassem⁵, Tadafumi Kato⁴⁶, John Kelsoe¹⁵, Sarah Kittel-Schneider⁴⁷, Po-Hsiu Kuo⁴⁸, Ichiro Kusumi⁴⁹, Barbara König⁵⁰, Gonzalo Laje⁵, Mikael Landén^{51,52}, Catharina Lavebratt¹¹, Marion Leboyer⁵³, Susan G. Leckband⁵⁴, Mario Maj⁵⁵, Mirko Manchia^{56,57}, Cynthia Marie-Claire⁵⁸, Lina Martinsson⁵⁹, Michael J. McCarthy^{15,60}, Susan L. McElroy⁶¹, Vincent Millischer^{11,62}, Marina Mitjans^{24,63}, Francis M. Mondimore²⁹, Palmiero Monteleone⁶⁴, Caroline M. Nievergelt¹⁵, Tomas Novák⁶⁵, Markus M. Nöthen²⁷, Claire O'Donovan³⁷, Norio Ozaki⁶⁶, Sergi Papiol^{30,41}, Andrea Pfennig⁶⁷, Claudia Pisanu²⁸, James B. Potash²⁹, Andreas Reif⁶⁸, Eva Reininghaus¹⁴, Hélène Richard-Lepouriel^{9,10}, Gloria Roberts⁶⁹, Guy A. Rouleau⁷⁰, Janusz K. Rybakowski³¹, Martin Schalling¹¹, Peter R. Schofield³⁴, Klaus Oliver Schubert^{6,71}, Eva C. Schulte^{30,41,72}, Barbara W. Schweizer²⁹, Giovanni Severino²⁸, Tatyana Shekhtman¹⁵, Paul D. Shilling¹⁵, Katzutaka Shimoda⁷³, Christian Simhandl⁷⁴, Claire M. Slaney³⁷, Alessio Squassina²⁸, Thomas Stamm², Pavla Stopkova⁶⁵, Fabian Streit³², Fasil Tekola-Ayele⁷⁵, Anbupalam Thalamuthu⁷⁶, Alfonso Tortorella⁷⁷, Gustavo Turecki²⁵, Julia Veeh⁶⁸, Eduard Vieta⁴⁴, Biju Viswanath⁷⁸, Stephanie H. Witt³², Peter P. Zandi⁷⁹, Martin Alda³⁷, Michael Bauer⁶⁷, Francis J. McMahon⁵, Philip B. Mitchell⁶⁹, Marcella Rietschel³², Thomas G. Schulze^{29,41,80} and Bernhard T. Baune^{1,81*}

Abstract

Background Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP. It also has been shown to have beneficial effects on disease-associated conditions, including sleep and cardiovascular disorders. However, the individual responses to Li treatment vary within and between diagnostic subtypes of BP (e.g. BP-I and BP-II) according to the clinical presentation. Moreover, long-term Li treatment has been linked to adverse side-effects that are a cause

*Correspondence:
Bernhard T. Baune
Bernhard.Baune@ukmuenster.de
Full list of author information is available at the end of the article

of concern and non-adherence, including the risk of developing chronic medical conditions such as thyroid and renal disease. In recent years, studies by the Consortium on Lithium Genetics (ConLiGen) have uncovered a number of genetic factors that contribute to the variability in Li treatment response in patients with BP. Here, we leveraged the ConLiGen cohort (N = 2064) to investigate the genetic basis of Li effects in BP. For this, we studied how Li response and linked genes associate with the psychiatric symptoms and polygenic load for medical comorbidities, placing particular emphasis on identifying differences between BP-I and BP-II.

Results We found that clinical response to Li treatment, measured with the Alda scale, was associated with a diminished burden of mania, depression, substance and alcohol abuse, psychosis and suicidal ideation in patients with BP-I and, in patients with BP-II, of depression only. Our genetic analyses showed that a stronger clinical response to Li was modestly related to lower polygenic load for diabetes and hypertension in BP-I but not BP-II. Moreover, our results suggested that a number of genes that have been previously linked to Li response variability in BP differentially relate to the psychiatric symptomatology, particularly to the numbers of manic and depressive episodes, and to the polygenic load for comorbid conditions, including diabetes, hypertension and hypothyroidism.

Conclusions Taken together, our findings suggest that the effects of Li on symptomatology and comorbidity in BP are partially modulated by common genetic factors, with differential effects between BP-I and BP-II.

Keywords Bipolar disorder, Lithium treatment, Psychiatric symptoms, Comorbidity, Genetics

Background

Lithium (Li) is the first-line maintenance treatment for bipolar disorders (BP). Multiple beneficial properties have been attributed to Li, including mood stabilization, cardio- and neuroprotection, circadian regulation, immunomodulation, and suicide prevention in patients with BP (Geoffroy et al. 2016; Volkmann et al. 2020; Xu et al. 2021; Queissner et al. 2021; Miller & McCall 2022; Rybakowski 2022; Chen et al. 2023; Szałach et al. 2023). Li is not exempt from acute side-effects, the most frequent being gastrointestinal complaints, that may cause non-adherence. However, it is the long-term adverse effects, including thyroid and kidney problems (Volkmann et al. 2020; Ferencztajn-Rochowiak et al. 2021), that cause most concern.

Individual responses to Li vary according to the clinical presentation of the disease. Reportedly, only about 30% of patients with BP have a full response to Li treatment. Various clinical, psychosocial and demographic factors that affect Li response have been described (Nunes et al. 2020; Ferencztajn-Rochowiak et al. 2021). Moreover, genetic studies have established Li response as a polygenic trait (Papiol et al. 2022). Previous work performed by the Consortium on Lithium Genetics (ConLiGen) has offered significant insights into the molecular mechanisms contributing to Li response (Amare et al. 2023), as well as the links with the polygenic scores of other psychiatric disorders (Amare et al. 2018; Schubert et al. 2021; Coombes et al. 2021) and with suicidal behavior (Yoshida et al. 2019) in BP. However, the relationships between Li response and disease features, particularly comorbidity, remain largely unexplored. Moreover, most studies have made no distinction between different diagnostic groups. Here, we used data from ConLiGen participants (N = 2064) to explore how the genetic factors that contribute to Li response

variability in patients with BP are associated with specific psychiatric symptoms and the polygenic load (i.e. genetic risk) for medical comorbid conditions, and whether these relationships differ between BP types I and II.

Methods

Study population

The ConLiGen cohort has been described elsewhere (Hou et al. 2016). Briefly, between 2003 and 2013, ConLiGen recruited over 2500 Li-treated individuals with bipolar spectrum disorders at various sites in Europe, the United States, Australia and East-Asia. The inclusion criteria consisted of a diagnosis of bipolar disorder type I (BP-I) or type II (BP-II), schizoaffective bipolar disorder or bipolar disorder not otherwise specified in accordance with the criteria established in the Diagnostic and Statistical Manual of Mental Disorders (DSM) versions III or IV, as well as Li treatment that lasted a minimum of six months with no additional mood stabilizers. Long-term responses to Li treatment were assessed using the Alda scale, where an A subscale rates the degree of response in the range 0–10 and a B subscale reflects the relationship between improvement and treatment. A total score, ranging from 0–10, is obtained by subtracting the B score from the A score (Manchia et al. 2013). Negative scores are set to 0. Here, we used a sample of 2064 ConLiGen participants with complete covariate phenotypes: sex, age-at-onset (AAO), age at recruitment (i.e. sample collection), diagnosis and recruitment site (used to establish population).

The Ethics Committee at the University of Heidelberg provided central approval for ConLiGen. Written informed consent from all participants was obtained according to the study protocols of each of the

participating sites and their institutions. All procedures were performed in accordance with the guidelines of the Declaration of Helsinki.

Genotype data

Genotyping, quality control (QC) and imputation of the ConLiGen cohort has been described elsewhere (Hou et al. 2016). Briefly, DNA genotyping by array was performed from peripheral blood samples in two batches of similar composition, originally referred to as “GWAS1” (N=1162) and “GWAS2” (N=1401). Standard procedures for QC and imputation using the 1000 Genomes Project reference panel were employed. Here, we used an updated ConLiGen dataset we previously described in detail (Herrera-Rivero et al. 2024), in which we re-imputed the combined ConLiGen batches using the Haplotype Reference Consortium (HRC) panel. This procedure increased the number of markers and the quality of the dataset, increasing its suitability for polygenic score (PGS) analyses. Single nucleotide polymorphisms (SNPs) in 37 genes that were previously reported to contribute to Li response in ConLiGen following a gene-level genome-wide analysis (Amare et al. 2023) were extracted from the dataset using a window of ± 1 kb from the start and end positions of the gene (according to the Ensembl hg19 genome build). Our final dataset contained 9374 SNPs corresponding to 34 Li response-linked genes and 2064 individuals with BP, from which 1669 had a diagnosis of BP-I and 370 of BP-II.

Phenotypes

Li response

We used the total Alda score as a measure of Li response. This was available for all 2064 individuals included in our study.

Psychiatric symptoms

Here, the psychiatric symptoms corresponded to the numbers of episodes of depression and mania, the presence of psychosis, alcohol and substance abuse, and of suicidal ideation. These variables were available for a maximum of 853 individuals from the GWAS1 batch.

Genetic risk for medical comorbidities

Based on the literature, we identified various conditions that are comorbid in BP and searched the PGS Catalog (Lambert et al. 2021) for publicly available PGSs for these. Weight files for the calculation of PGSs for various traits, such as disorders of sleep and metabolism, were downloaded from the PGS Catalog and used for allelic scoring in the total ConLiGen sample with plink 1.9 (Chang et al. 2015). Standardized sum scores were used for analysis.

Because of incomplete compatibility between PGS SNPs and variants in the ConLiGen dataset, only PGSs with compatibility $>78\%$ were used. These corresponded to the following traits: chronotype (PGS ID: PGS002209), sleep duration (PGS ID: PGS002196), insomnia (PGS ID: PGS002149), hypertension (PGS ID: PGS002047), hypothyroidism (PGS ID: PGS001816) and type 2 diabetes (PGS ID: PGS003118) (Privé et al. 2022; Ma et al. 2022) (Suppl. Table 1). Traits excluded due to lower compatibility included cardiovascular disorders, obesity, migraine and asthma.

Statistical analyses

Associations between total Alda scores and psychiatric symptoms were tested using robust linear/logistic regression models with the “robustbase” R package ($n_{\max}=853$). Models were adjusted for sex, AAO and age. Associations between total Alda scores and PGSs for comorbid conditions were tested using partial Spearman correlation with the “ppcor” R package ($n_{\max}=2064$). Models were adjusted for sex, AAO, age and population. SNP-phenotype associations were tested using linear/logistic regression models with plink 1.9. Models were adjusted for sex, AAO, age, population, total Alda score and the first eight dimensions coming from a principal components analysis of the genotypes. When testing associations using all individuals, all models were also adjusted for the differential BP diagnosis. All associations were also tested separately for BP-I and BP-II. For exploratory purposes, significance was set to nominal (i.e. unadjusted) $p < 0.05$ and $p < 0.01$ for total Alda score and SNP-phenotype associations, respectively.

Results

To explore how Li response genes are associated with specific psychiatric symptoms and the polygenic load for medical comorbid conditions, and whether these relationships differ between BP types I and II, we used a sample of 2064 individuals with BP from the ConLiGen cohort. From these, 1197 (58%) were females, 1669 (80.1%) had a diagnosis of BP-I and 370 (17.9%) were diagnosed with BP-II. The mean AAO in the sample was 25 ± 11 years, while the mean age at recruitment was 47 ± 14 years. The mean total Alda score was 4.22 ± 3.16 points, with 29.8% of the patients being categorized as good responders (total Alda score ≥ 7). Compared to BP-I, BP-II patients were slightly older at disease onset (28 ± 12 vs 24 ± 10 years) and recruitment (50 ± 14 vs 47 ± 14 years), and had higher rates of females (61.9% vs 57.2%) and good Li responders (34.1% vs 28.2%). However, the mean total Alda scores were very similar (4.6 ± 3.2 vs 4.2 ± 3.1 points).

First, we explored the association between Li response and psychiatric symptoms/PGSs for comorbid conditions. Using a nominal significance threshold ($p < 0.05$), we found that the total Alda scores showed a negative relationship with all psychiatric symptom variables in all BP ($n_{\max} = 835$) and BP-I ($n_{\max} = 665$) individuals. However, in BP-II individuals ($n_{\max} = 153$), the total Alda scores showed a negative relationship only with the number of depressive episodes (Fig. 1A). Noticeably, these results survived false discovery rate correction ($FDR < 0.05$). Furthermore, the total Alda scores also correlated negatively with the PGSs for diabetes and hypertension in all BP ($N = 2064$) and BP-I ($N = 1669$) individuals, and with the PGS for insomnia in all BP, BP-I and BP-II ($N = 370$) individuals (Fig. 1B). However, none of the nominal associations with PGSs survived FDR correction in our sample.

Second, we explored the association between genes previously linked to Li response and psychiatric symptoms/PGSs for comorbid conditions. Using a nominal significance threshold ($p < 0.01$) as indicative of suggestive association, we found that 32 of the 34 genes tested were suggested to associate with specific psychiatric symptoms and/or PGSs for comorbid conditions (Fig. 2, Suppl.Tables.2–7). The most significant hits were for the number of manic episodes, with *SLC13A3* as top gene in BP-I and *TNRC6C* in BP-II, followed by the number of depressive episodes, with *MTSS1* as top gene in BP-I and *DNAH14* in BP-II (Table 1).

Taken together, 22 of the 34 genes tested were nominally associated with at least one psychiatric symptom and one PGS in at least one of the tests performed (i.e. all BP, BP-I and BP-II). Noticeably, some of the Li response

genes were suggested to associate with all the phenotypes that we studied in at least one of the tests. We also observed that genes with the most overlaps, including *RNLS*, *GRIN2A*, *CSMD2*, *DNAH14* and *TTC39B* (Table 2), represented the most significant hits obtained in BP-I or BP-II for various PGSs for comorbid conditions (Table 1).

Finally, we looked into the overlapping and non-overlapping genes between the BP-I and BP-II analyses (Table 3). Here, we observed that, for example, *GRIN2A* was suggested to relate to the number of depressive episodes, the presence of alcohol abuse, and the polygenic contribution to chronotype, diabetes and hypertension in both major types of BP. However, it was suggested to be linked to the presence of psychosis and suicidal ideation, and the polygenic contribution to sleep duration and hypothyroidism in BP-I only, while relating to the number of manic episodes and the genetic load for insomnia only in BP-II.

Discussion

We showed that positive responses to Li treatment in patients with BP are generally more beneficial to those patients diagnosed with BP-I than to those with a BP-II diagnosis, and that genes linked to Li response also contribute to the clinical presentation of the disorder in terms of psychiatric symptomatology and, potentially, the risk of medical comorbid conditions. This may partly explain why Li responses usually vary according to clinical features, and why clinical and psychosocial factors can only partially predict Li responses (Tondo et al. 2001; Ferensztajn-Rochowiak et al. 2021).




Fig. 1 Links between phenotypes and Li responses in ConLiGen. **A** Association test results between total Alda scores and psychiatric symptoms. Shown are the nominal p-values ($-\log_{10}$) and z-values (effect) obtained from robust linear/logistic regression models. **B** Correlation test results between total Alda scores and PGSs for comorbid conditions. Shown are the nominal p-values ($-\log_{10}$) and correlation coefficients (effect) obtained from partial correlation models using the Spearman method




Fig. 2 Visual integration of nominal findings for Li response genes. Shapes depict the diagnostic group analyzed while colors refer to the phenotypes nominally associated with the gene in our analyses, except for the blue color, which localized even the genes not analyzed in this study that were reported by Amare et al. 2023 as contributors to Li response in ConLiGen

Often, the efficacy of Li treatment in BP is assessed without making distinction between BP types and/or is focused on manic-depressive episodes, with disregard of other disease-associated afflictions. However, some studies have shown that Li impacts differently the frequency and duration of mood episodes in BP-I and BP-II (Tondo et al. 2001), which might relate to stronger effects on acute manic than depressive episodes (Fountoulakis et al. 2022). Moreover, it is plausible that the beneficial effects of Li treatment on psychiatric symptomatology are related to its effects on other health issues associated with BP, such as improving inflammation and sleep (Geoffroy et al. 2016; Szałach et al. 2023). The results of our study are in agreement. When we explored the association between Li response and psychiatric symptoms/PGSs for comorbid conditions, our observations suggested that better responses to Li treatment diminish the burden of most psychiatric symptoms in patients with BP-I, but only that of depression in patients with BP-II, and that better Li response differentially correlates with lower genetic burden predisposing to comorbid conditions, such as insomnia, diabetes and hypertension. In addition, when we explored the association between genes previously linked to Li response and psychiatric symptoms/PGSs for comorbid conditions, we found that Li response genes were more strongly associated with manic than depressive episodes in both BP-I and BP-II, and that Li response genes were modestly but differentially associated with other features relevant to the

clinical presentation, including, for example, suicidal ideation, psychosis and polygenic load for insomnia and hypothyroidism, in both BP-I and BP-II. Noticeably, the fact that the results of our genetic analyses did not exactly match those obtained for the total Alda score, where the positive effects of Li showed a clear bias towards BP-I, also suggest important gene-environment interactions.

Despite the exploratory character of our genetic study, we believe that it suggests plausible candidate genes and offers some valuable insights into the molecular mechanisms underlying inter-individual variability in Li response. For example, renalase (*RNLS*) was one of the most highlighted genes in our study. In addition to its link to Li response in BP (Amare et al. 2023), serum renalase levels have been reported to be lower in patients with schizophrenia (SCZ) than in control individuals (Catak et al. 2019), and Li response was previously shown to inversely associate with the genetic risk for SCZ (Amare et al. 2018). *RNLS* is thought to modulate blood pressure and cardiac function, and has been associated with metabolic and cardiovascular alterations as well as kidney disease (Vijayakumar & Mahapatra 2022), all of which are affected by Li. Similar are the cases of *CSMD2* and *GRIN2A*, which are involved in the control of the complement cascade and N-methyl-D-aspartate (NMDA) receptor activity, respectively. Polymorphisms in both genes have also been associated with SCZ (Tang et al. 2006; Håvik et al. 2011) and their respective functions are

Table 1 Phenotype-based summary of findings for the association analyses between Li response genes and psychiatric symptoms/PGSs for comorbid conditions in ConLiGen

Phenotype	N	# Cases	# Controls	# SNPs p < 0.01	# Genes	Top gene	Top # SNPs p < 0.01	Lowest p
<i>All BP</i>								
# Manic episodes	724	–	–	38	9	<i>SLC13A3</i>	11	2.48E–08
# Depressive episodes	789	–	–	225	12	<i>FGD4</i>	75	5.15E–06
Alcohol abuse	835	140	695	114	9	<i>ELOVL6</i>	5	1.11E–04
Substance abuse	832	135	697	143	9	<i>ADGRD1</i>	45	4.17E–04
Psychosis	692	342	350	55	11	<i>GRIN2A</i>	12	7.83E–04
Suicidal ideation	660	321	339	10	6	<i>DNAH14</i>	1	2.31E–03
Insomnia PGS	2064	–	–	57	8	<i>CSMD2</i>	6	1.73E–04
Sleep duration PGS	2064	–	–	211	12	<i>DNAH14</i>	133	1.12E–04
Chronotype PGS	2064	–	–	81	7	<i>GRIN2A</i>	47	4.06E–04
Diabetes PGS	2064	–	–	111	12	<i>CSMD2</i>	33	6.28E–04
Hypertension PGS	2064	–	–	34	7	<i>TTC39B</i>	5	9.57E–05
Hypothyroidism PGS	2064	–	–	82	7	<i>MTSS1</i>	42	4.73E–04
<i>BP-I diagnosis</i>								
# Manic episodes	641	–	–	48	10	<i>SLC13A3</i>	11	2.15E–08
# Depressive episodes	632	–	–	193	13	<i>MTSS1</i>	12	1.52E–06
Alcohol abuse	665	129	536	131	9	<i>CSMD2</i>	52	1.34E–04
Substance abuse	662	121	541	121	5	<i>ADGRD1</i>	52	4.13E–04
Psychosis	564	318	246	87	10	<i>CSMD2</i>	21	7.17E–04
Suicidal ideation	530	264	266	41	6	<i>MTSS1</i>	1	2.15E–04
Insomnia PGS	1669	–	–	48	6	<i>ALPK1</i>	4	3.92E–04
Sleep duration PGS	1669	–	–	174	11	<i>RNLS</i>	3	4.37E–05
Chronotype PGS	1669	–	–	35	5	<i>RNLS</i>	2	1.76E–04
Diabetes PGS	1669	–	–	74	13	<i>TTC39B</i>	1	6.78E–04
Hypertension PGS	1669	–	–	29	7	<i>TTC39B</i>	1	6.81E–04
Hypothyroidism PGS	1669	–	–	38	8	<i>CSMD2</i>	4	6.95E–04
<i>BP-II diagnosis</i>								
# Manic episodes	68	–	–	113	10	<i>TNRC6C</i>	3	3.76E–79
# Depressive episodes	141	–	–	128	11	<i>DNAH14</i>	6	3.12E–08
Alcohol abuse	153	7	146	7	5	<i>TNRC6C</i>	2	1.80E–03
Substance abuse	153	8	145	0	0	–	–	–
Psychosis	115	12	103	353	7	<i>TMEM131</i>	46	1.08E–03
Suicidal ideation	118	48	70	79	7	<i>TTC39B</i>	24	2.49E–03
Insomnia PGS	370	–	–	209	7	<i>GRIN2A</i>	38	2.65E–04
Sleep duration PGS	370	–	–	64	9	<i>DNAH14</i>	16	2.95E–04
Chronotype PGS	370	–	–	32	7	<i>GRIN2A</i>	19	1.81E–03
Diabetes PGS	370	–	–	97	9	<i>MTSS1</i>	6	2.01E–04
Hypertension PGS	370	–	–	130	10	<i>TMEM196</i>	27	3.21E–04
Hypothyroidism PGS	370	–	–	70	7	<i>BMF</i>	12	1.92E–04

reported targets of Li effects (Ghasemi & Dehpour 2011; Yu et al. 2015).

The investigation of how Li response measured by the Alda scale and Li response genes associate with the genetic predisposition to comorbid (medical) conditions is an important strength of our study. To our knowledge, this has not been investigated before. A high rate

of medical comorbidity in BP, including cardiometabolic conditions, thyroid and kidney disease, is associated with worse clinical presentation and course, as well as higher mortality and increased socioeconomic burden (Sylvia et al. 2015). Although the risk of comorbidity can be exacerbated by pharmacological treatment, as discussed above, Li has shown beneficial effects on various

Table 2 Gene-based summary of findings for the association analyses between Li response genes and psychiatric symptoms/PGSs for comorbid conditions in ConLiGen

Gene	Chr	Gene start (– 1 kb)	Gene end (+ 1 kb)	# tested SNPs	Psychiatric phenotype count			PGS phenotype count			Max. # phenotypes
					All	BP-I	BP-II	All	BP-I	BP-II	
CSMD2	1	33,978,609	34,632,443	1064	4	5	3	5	5	5	12
S100A11	1	152,003,982	152,021,383	14	0	1	0	0	0	0	1
SLC9C2	1	173,468,603	173,573,233	179	2	2	1	1	2	0	5
DNAH14	1	225,082,964	225,587,996	1417	5	5	3	3	3	5	11
TMEM131	2	98,371,799	98,613,388	358	0	0	1	0	0	1	2
RBM47	4	40,424,272	40,633,892	164	0	0	3	0	0	1	4
ELOVL6	4	110,966,002	111,121,355	261	2	2	3	2	3	1	7
ALPK1	4	113,205,665	113,364,776	301	1	2	3	4	3	4	10
ZBTB2	6	151,684,252	151,713,683	43	1	1	2	1	0	0	3
TMEM196	7	19,757,933	19,814,221	108	2	1	1	1	0	1	4
ERVW-1	7	92,096,694	92,108,300	19	0	0	0	0	0	0	0
FAM133B	7	92,189,107	92,220,708	50	1	0	0	0	0	0	1
MTSS1	8	125,562,031	125,741,730	499	4	4	1	2	3	4	8
TTC39B	9	15,162,620	15,308,358	408	3	3	4	4	5	2	11
TOR1B	9	132,564,432	132,574,560	20	0	0	0	1	0	0	1
TOR1A	9	132,574,223	132,587,413	32	0	0	0	1	0	0	1
TYSND1	10	71,896,737	71,907,432	40	0	1	1	0	0	0	2
RNLS	10	90,032,621	90,345,287	628	5	5	3	6	6	4	12
FANK1	10	127,584,108	127,699,161	250	1	1	0	2	3	0	4
FGD4	12	32,551,463	32,799,984	882	5	3	3	5	2	3	12
OR2AP1	12	55,967,199	55,970,128	7	1	0	0	1	1	1	3
ADGRD1	12	131,437,452	131,627,014	603	5	5	1	6	3	4	12
RGCC	13	42,030,695	42,046,018	35	1	1	0	1	1	0	2
BMF	15	40,379,091	40,402,093	16	0	0	0	0	0	1	1
GRIN2A	16	9,851,376	10,277,611	1624	5	4	3	3	5	4	12
CHP2	16	23,764,948	23,771,272	10	0	0	0	0	0	0	0
MYLK3	16	46,739,891	46,825,319	0	0	0	0	0	0	0	0
C16orf87	16	46,829,519	46,866,323	0	0	0	0	0	0	0	0
TRAF4	17	27,070,002	27,078,974	8	2	0	0	0	1	1	4
TMEM98	17	31,253,928	31,273,124	33	0	0	0	0	1	1	2
CDK3	17	73,995,987	74,003,080	4	1	1	0	0	0	0	1
TNRC6C	17	75,999,249	76,105,916	153	2	2	2	3	2	2	7
GNG8	19	47,136,333	47,138,942	0	0	0	0	0	0	0	0
ZFP28	19	57,049,317	57,069,169	46	0	1	0	0	0	0	1
OCSTAMP	20	45,168,585	45,180,213	10	0	0	0	0	0	1	1
SLC13A3	20	45,185,463	45,305,714	58	1	1	1	1	0	0	3
CRYBB3	22	25,594,817	25,604,330	31	2	2	1	0	1	3	5

systems. Therefore, it becomes crucial to gain a better understanding of the relationship between the effects of Li and medical comorbidity in BP. In this context, even when our PGS analyses resulted in only nominally significant findings, these suggested that common genetic factors link Li response and other conditions, particularly insomnia, in BP, and pinpointed potential contributing

genes. In BP, sleep disturbances, from which the most frequent is insomnia, are not only highly prevalent, but an important predictor of quality of life, mood swings, suicide attempts, cognitive function and relapse rates (Steardo et al. 2019). Therefore, our observations might have implications for the prediction of Li response in BP

Table 3 Li response genes nominally associated with psychiatric symptoms/PGSs for comorbid conditions in ConLiGen. Shown are the overlapping and non-overlapping genes between BP-I and BP-II diagnostic groups

Phenotype	BP-I only	BP-II only	Overlap
# Manic episodes	<i>ADGRD1, FANK1, FGD4, SLC13A3, SLC9C2</i>	<i>ALPK1, CSMD2, ELOVL6, GRIN2A, TTC39B</i>	<i>CRYBB3, DNAH14, RNLS, TNRC6C, ZBTB2</i>
# Depressive episodes	<i>ADGRD1, CDK3, MTSS1, RGCC, S100A11, TTC39B, TYSND1</i>	<i>ELOVL6, RBM47, SLC13A3, TMEM196, ZBTB2</i>	<i>ALPK1, CSMD2, DNAH14, FGD4, GRIN2A, RNLS</i>
Alcohol abuse	<i>ADGRD1, CRYBB3, CSMD2, DNAH14, ELOVL6, RNLS, SLC9C2</i>	<i>ALPK1, FGD4, TNRC6C</i>	<i>GRIN2A, TTC39B</i>
Substance abuse	<i>ADGRD1, CSMD2, MTSS1, RNLS, TTC39B</i>	–	–
Psychosis	<i>ALPK1, FGD4, GRIN2A, MTSS1, TMEM196, TNRC6C, ZFP28</i>	<i>ADGRD1, RBM47, TMEM131, TTC39B</i>	<i>CSMD2, DNAH14, ELOVL6</i>
Suicidal ideation	<i>ADGRD1, CSMD2, DNAH14, GRIN2A, MTSS1</i>	<i>FGD4, MTSS1, RBM47, SLC9C2, TTC39B, TYSND1</i>	<i>RNLS</i>
Insomnia PGS	<i>ALPK1, CSMD2, TTC39B</i>	<i>ADGRD1, GRIN2A, OR2AP1, TMEM131</i>	<i>DNAH14, MTSS1, RNLS</i>
Sleep duration PGS	<i>ELOVL6, FANK1, GRIN2A, RNLS, SLC9C2</i>	<i>FGD4, RBM47, TMEM98</i>	<i>ADGRD1, ALPK1, CRYBB3, CSMD2, DNAH14, TTC39B</i>
Chronotype PGS	<i>ELOVL6, RNLS</i>	<i>CRYBB3, DNAH14, MTSS1, TNRC6C</i>	<i>ALPK1, CSMD2, GRIN2A</i>
Diabetes PGS	<i>ADGRD1, FANK1, OR2AP1, SLC9C2, TTC39B</i>	<i>ALPK1, TNRC6C</i>	<i>CSMD2, DNAH14, ELOVL6, FGD4, GRIN2A, MTSS1, RNLS</i>
Hypertension PGS	<i>FANK1, TNRC6C, TRAF4</i>	<i>ADGRD1, CRYBB3, CSMD2, DNAH14, OCSTAMP, TMEM196</i>	<i>FGD4, GRIN2A, RNLS, TTC39B</i>
Hypothyroidism PGS	<i>GRIN2A, TMEM98, TNRC6C, TTC39B</i>	<i>ALPK1, BMF, TRAF4</i>	<i>ADGRD1, CSMD2, MTSS1, RNLS</i>

patients as well as for disease management. Nevertheless, more studies will be required.

Conclusions

Taken together, our findings suggest that the effects of Li on symptomatology and comorbidity in BP are partially modulated by common genetic factors, with differential effects between BP-I and BP-II. These findings might pave the way towards the development of more personalized treatment strategies for patients with BP.

Abbreviations

AAO	Age at disease onset
BP	Bipolar disorders
ConLiGen	Consortium on Lithium Genetics
Li	Lithium
PGS	Polygenic score
SNP	Single nucleotide polymorphism

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40345-024-00341-y>.

Supplementary Material 1.

Author contributions

MHR: study conception and design, data analysis, manuscript preparation. BTB: study conception, supervision, manuscript editing. All other authors are ConLiGen members, which contributed to the clinical and genetic data used in the study, and provided overall feedback on the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. The study was supported by the joint project "Individualisation in Changing Environments"

(InChangE) of the universities of Münster and Bielefeld, Germany. The project received funding from the programme "Profilbildung 2020", an initiative of the Ministry of Culture and Science of the State of Northrhine Westphalia. The sole responsibility for the content of this publication lies with the authors. The primary sources of funding for ConLiGen were grants RI 908/7-1, FOR2107 and RI 908/11-1 from the Deutsche Forschungsgemeinschaft (Marcella Rietschel) and grant NO 246/10-1 (Markus M. Nöthen) and grant ZIA-MH00284311 from the Intramural Research Program of the National Institute of Mental Health (ClinicalTrials.gov identifier: NCT00001174). The genotyping was funded in part by the German Federal Ministry of Education and Research through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the e:Med Programme (Thomas G. Schulze, Marcella Rietschel and Markus M. Nöthen). The Canadian part of the study was supported by grant #166098 from the Canadian Institutes of Health Research and by a grant from Genome Atlantic/Research Nova Scotia (Martin Alda). Collection and phenotyping of the Australian University of New South Wales sample was funded by Program Grant 1037196 from the Australian National Health and Medical Research Council (Philip B. Mitchell, Peter R. Schofield, Janice M. Fullerton), and acknowledges support from Lansdowne Foundation, Betty Lynch OAM (dec) and the Janette Mary O'Neill Fellowship. AT Amare is currently supported by National Health and Medical Research Council (NHMRC) Emerging Leadership (EL1) Investigator Grant (APP2008000). The collection of the Barcelona sample was supported by grants PI080247, PI1200906, PI12/00018, 20145GR1636, 20145GR398, and MSII14/00030 from the Centro de Investigación en Red de Salud Mental, Institut d'Investigacions Biomèdiques August Pi i Sunyer, the Centres de Recerca de Catalunya Programme/Generalitat de Catalunya, and the Miguel Servet II and Instituto de Salud Carlos III. The Swedish Research Council, the Stockholm County Council, Karolinska Institutet and the Söderström-Königska Foundation supported this research through grants awarded to Lena Backlund, Louise Frisen, Catharina Lavebratt and Martin Schalling. The collection of the Geneva sample was supported by grants Synapsy–The Synaptic Basis of Mental Diseases 51NF40-158776 and 32003B-125469 from the Swiss National Foundation. The work by the French group was supported by INSERM (Institut National de la Santé et de la Recherche Médicale), AP-HP (Assistance Publique des Hôpitaux de Paris), the Fondation FondaMental (RTS Santé Mentale), and the labex Bio-PSY (Investissements d'Avenir program managed by the ANR under reference ANR-11-IDEX-0004-02). The collection of the Romanian sample was supported by a grant from UEFISCDI, Bucharest, Romania (grants PCCA-89/2012; PCE-203/2021) to Maria Grigoriou-Serbanescu. The collection

of the Czech sample was supported by the project Nr. LO1611 with a financial support from the MEYS under the NPU I program and by the Czech Science Foundation, grant Nr. 17-07070S. Biju Viswanath is funded by the Intermediate (Clinical and PublicHealth) Fellowship (IA/CPHI/20/1/505266) of the DBT/Wellcome Trust India Alliance.

Availability of data and materials

The data that support the findings of this study are available from ConLiGen, but restrictions apply to their availability.

Declarations

Ethics approval and consent to participate

The Ethics Committee at the University of Heidelberg provided central approval for ConLiGen. Written informed consent from all participants was obtained according to the study protocols of each of the participating sites and their institutions. All procedures were performed in accordance with the guidelines of the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

Eduard Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbvie, Almirall, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, GH Research, Glaxo-Smith-Kline, Janssen, Lundbeck, Orion, Otsuka, Pfizer, Roche, Rovi, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), the Stanley Medical Research Institute and Viatrix. Michael Bauer has received grants from the Deutsche Forschungsgemeinschaft (DFG), and Bundesministeriums für Bildung und Forschung (BMBF), and served as consultant, advisor or CME speaker for the following entities: Allergan, Aristo, Janssen, Lilly, Lundbeck, neuraxpharm, Otsuka, Sandoz, Servier and Sunovion outside the submitted work. Sarah Kittel-Schneider has received grants and served as consultant, advisor or speaker for the following entities: Medice Arzneimittel Pütter GmbH and Takeda. Bernhard Baune has received grants and served as consultant, advisor or CME speaker for the following entities: AstraZeneca, Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Servier, the National Health and Medical Research Council, the Fay Fuller Foundation, the James and Diana Ramsay Foundation. Tadafumi Kato received honoraria for lectures, manuscripts, and/or consultancy, from Kyowa Hakkō Kirin Co, Ltd, Eli Lilly Japan K.K., Otsuka Pharmaceutical Co, Ltd, GlaxoSmithKline K.K., Taisho Toyama Pharmaceutical Co, Ltd, Dainippon Sumitomo Pharma Co, Ltd, Meiji Seika Pharma Co, Ltd, Pfizer Japan Inc., Mochida Pharmaceutical Co, Ltd, Shionogi & Co, Ltd, Janssen Pharmaceutical K.K., Janssen Asia Pacific, Yoshitomyakuhin, Astellas Pharma Inc, Wako Pure Chemical Industries, Ltd, Wiley Publishing Japan, Nippon Boehringer Ingelheim Co Ltd, Kanae Foundation for the Promotion of Medical Science, MSD K.K., Kyowa Pharmaceutical Industry Co, Ltd and Takeda Pharmaceutical Co, Ltd. Tadafumi Kato also received a research grant from Takeda Pharmaceutical Co, Ltd. Peter Falkai has received grants and served as consultant, advisor or CME speaker for the following entities Abbott, Glaxo-SmithKline, Janssen, Essex, Lundbeck, Otsuka, Gedeon Richter, Servier and Takeda as well as the German Ministry of Science and the German Ministry of Health. Eva Reininghaus has received grants and served as consultant, advisor or CME speaker for the following entities: Janssen and Institut Allergosan. Mikael Landén has received lecture honoraria from Lundbeck. Kazufumi Akiyama has received consulting honoraria from Taisho Toyama Pharmaceutical Co, Ltd. Scott Clark has received grants, or data and served as consultant, advisor or CME speaker for the following entities: Otsuka Australia, Lundbeck Australia, Janssen-Cilag Australia, Servier Australia, Viatrix. Bruno Etain received honoraria from Sanofi Aventis. The rest of authors have no conflicts of interest to disclose.

Author details

¹Department of Psychiatry, University of Münster and Joint Institute for Individualisation in a Changing Environment (JICE), University of Münster and Bielefeld University, Albert-Schweitzer-Campus 1, Building A9, 48149 Münster, Germany. ²Department of Psychiatry and Psychotherapy, Charité,

Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany. ³Fliedner Klinik Berlin, Berlin, Germany. ⁴Department of Biological Psychiatry and Neuroscience, Dokkyo Medical University School of Medicine, Mibu, Japan. ⁵Intramural Research Program, National Institute of Mental Health, National Institutes of Health, US Department of Health & Human Services, Baltimore, USA. ⁶Discipline of Psychiatry, School of Medicine, University of Adelaide, Adelaide, SA, Australia. ⁷Unit of Clinical Pharmacology, Hospital University Agency of Cagliari, Cagliari, Italy. ⁸Unitat de Zoologia i Antropologia Biològica (Dpt. Biologia Evolutiva, Ecologia i Ciències Ambientals), Facultat de Biologia and Institut de Biomedicina (IBUB), University of Barcelona, CIBERSAM, Barcelona, Spain. ⁹Department of Psychiatry, Division of Psychiatric Specialties, Geneva University Hospitals, Geneva, Switzerland. ¹⁰Faculty of Medicine, University of Geneva, Geneva, Switzerland. ¹¹Department of Molecular Medicine and Surgery and Center for Molecular Medicine at Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden. ¹²Département de Psychiatrie et de Médecine Addictologique, INSERM UMR-S 1144, Université Paris Cité, AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière, F. Widal, Paris, France. ¹³Bipolar Disorder Program, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain. ¹⁴Department of Psychiatry and Psychotherapeutic Medicine, Research Unit for Bipolar Affective Disorder, Medical University of Graz, Graz, Austria. ¹⁵Department of Psychiatry, University of California San Diego, San Diego, USA. ¹⁶Department of Health Sciences Research, Mayo Clinic, Rochester, USA. ¹⁷Department of Psychiatry and Psychology, Mayo Clinic, Rochester, USA. ¹⁸The Neuromodulation Unit, McGill University Health Centre, Montreal, Canada. ¹⁹Department of Psychiatry & Center of Sleep Disorders, National Taiwan University Hospital, Taipei, Taiwan. ²⁰Human Genomics Research Group, Department of Biomedicine, University Hospital Basel, Basel, Switzerland. ²¹Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland. ²²Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, Germany. ²³Mental Health Research Group, IMIM-Hospital del Mar, Barcelona, Spain. ²⁴Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain. ²⁵Douglas Mental Health University Institute, McGill University, Montreal, Canada. ²⁶Psychiatric Genetic Unit, Poznan University of Medical Sciences, Poznań, Poland. ²⁷Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany. ²⁸Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy. ²⁹Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, USA. ³⁰Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Munich, Germany. ³¹Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznań, Poland. ³²Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. ³³Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. ³⁴Neuroscience Research, Australia and School of Biomedical Sciences, University of New South Wales, Sydney, Australia. ³⁵Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, San Martín de Porres, Peru. ³⁶Service de Psychiatrie, Hôpital Charles Perrens, Bordeaux, France. ³⁷Department of Psychiatry, Dalhousie University, Halifax, Canada. ³⁸Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Clinical Psychiatric Hospital, Bucharest, Romania. ³⁹Mood Disorders Center of Ottawa, Ottawa, Canada. ⁴⁰Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan. ⁴¹Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany. ⁴²Program for Quantitative Genomics, Harvard School of Public Health and HSL Institute for Aging Research, Harvard Medical School, Boston, USA. ⁴³Univ. Paris Est Créteil, INSERM, IMRB, Translational Neuropsychiatry, Fondation FondaMental, Créteil, France. ⁴⁴Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, ISCIII, Barcelona, Spain. ⁴⁵Service de Psychiatrie et Psychologie Clinique, Centre Psychothérapique de Nancy - Université, Nancy, France. ⁴⁶Department of Psychiatry & Behavioral Science, Graduate School of Medicine, Juntendo University, Tokyo, Japan. ⁴⁷Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Würzburg, Würzburg, Germany. ⁴⁸Department of Public Health & Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. ⁴⁹Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan. ⁵⁰Department of Psychiatry and Psychotherapeutic Medicine, Landesklinikum

Neunkirchen, Neunkirchen, Austria. ⁵¹Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the Gothenburg University, Gothenburg, Sweden. ⁵²Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁵³Univ. Paris Est Créteil, INSERM, IMRB, Translational Neuropsychiatry, AP-HP, Mondor University Hospital, DMU Impact, Fondation FondaMental, Créteil, France. ⁵⁴Office of Mental Health, VA San Diego Healthcare System, California, USA. ⁵⁵Department of Psychiatry, University of Campania 'Luigi Vanvitelli', Caserta, Italy. ⁵⁶Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. ⁵⁷Department of Pharmacology, Dalhousie University, Halifax, Canada. ⁵⁸Université Paris Cité, Inserm UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France. ⁵⁹Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden. ⁶⁰Department of Psychiatry, VA San Diego Healthcare System, San Diego, CA, USA. ⁶¹Department of Psychiatry, Lindner Center of Hope/University of Cincinnati, Cincinnati, USA. ⁶²Department of Psychiatry and Psychotherapy, Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria. ⁶³Department of Genetics, Microbiology and Statistics, Faculty of Biology, Institut de Biomedicina de La Universitat de Barcelona (IBUB), University of Barcelona, Barcelona, Spain. ⁶⁴Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, Italy. ⁶⁵National Institute of Mental Health, Klecany, Czech Republic. ⁶⁶Department of Psychiatry & Department of Child and Adolescent Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan. ⁶⁷Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Medical Faculty, Technische Universität Dresden, Dresden, Germany. ⁶⁸Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt, Germany. ⁶⁹School of Psychiatry, University of New South Wales, Sydney, Australia. ⁷⁰Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada. ⁷¹Northern Adelaide Local Health Network, Mental Health Services, Adelaide, Australia. ⁷²Department of Psychiatry and Psychotherapy, University Hospital Bonn, Medical Faculty University of Bonn, Bonn, Germany. ⁷³Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Japan. ⁷⁴Medical Faculty, Bipolar Center Wiener Neustadt, Sigmund Freud University, Vienna, Austria. ⁷⁵Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, USA. ⁷⁶Centre for Healthy Brain Ageing (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia. ⁷⁷Department of Psychiatry, University of Perugia, Perugia, Italy. ⁷⁸Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore 560029, India. ⁷⁹Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. ⁸⁰Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA. ⁸¹Department of Psychiatry, Melbourne Medical School, University of Melbourne and The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia.

Received: 28 November 2023 Accepted: 2 May 2024
Published online: 12 June 2024

References

- Amare AT, Schubert KO, International Consortium on Lithium Genetics (ConLi+Gen), et al. Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder. *A Genome-Wide Association Study*. *JAMA Psychiatry*. 2018;75(1):65–74. <https://doi.org/10.1001/jamapsychiatry.2017.3433>
- Amare AT, Thalamuthu A, Schubert KO, et al. Association of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder. *Mol Psychiatry*. 2023. <https://doi.org/10.1038/s41380-023-02149-1>. [10.1038/s41380-023-02149-1](https://doi.org/10.1038/s41380-023-02149-1).
- Catak Z, Kocdemir E, Ugur K, et al. A novel biomarker renalase and its relationship with its substrates in schizophrenia. *J Med Biochem*. 2019;38(3):299–305. <https://doi.org/10.2478/jomb-2018-0031>.
- Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4:7. <https://doi.org/10.1186/s13742-015-0047-8>.
- Chen PH, Hsiao CY, Chiang SJ, et al. Cardioprotective potential of lithium and role of fractalkine in euthymic patients with bipolar disorder. *Aust N Z J Psychiatry*. 2023;57(1):104–14. <https://doi.org/10.1177/00048674211062532>.
- Coombes BJ, Millischer V, Batzler A, et al. Association of attention-deficit/hyperactivity disorder and depression polygenic scores with lithium response: a consortium for lithium genetics study. *Complex Psychiatry*. 2021;7(3–4):80–9. <https://doi.org/10.1159/000519707>.
- Ferenzstajn-Rochowiak E, Chłopocka-Woźniak M, Rybakowski JK. Ultra-long-term lithium therapy: all-important matters and a case of successful 50-year lithium treatment. *Braz J Psychiatry*. 2021;43(4):407–13. <https://doi.org/10.1590/1516-4446-2020-1111>.
- Fountoulakis KN, Tohen M, Zarate CA Jr. Lithium treatment of Bipolar disorder in adults: a systematic review of randomized trials and meta-analyses. *Eur Neuropsychopharmacol*. 2022;54:100–15. <https://doi.org/10.1016/j.euronuro.2021.10.003>.
- Geoffroy PA, Samalin L, Llorca PM, Curis E, Bellivier F. Influence of lithium on sleep and chronotypes in remitted patients with bipolar disorder. *J Affect Disord*. 2016;204:32–9. <https://doi.org/10.1016/j.jad.2016.06.015>.
- Ghasemi M, Dehpour AR. The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. *Trends Pharmacol Sci*. 2011;32(7):420–34. <https://doi.org/10.1016/j.tips.2011.03.006>.
- Håvik B, Le Hellard S, Rietschel M, et al. The complement control-related genes C5MD1 and C5MD2 associate to schizophrenia. *Biol Psychiatry*. 2011;70(1):35–42. <https://doi.org/10.1016/j.biopsych.2011.01.030>.
- Herrera-Rivero M, Gutiérrez-Fragoso K; International Consortium on Lithium Genetics (ConLi+Gen), Kurtz J, Baune BT. Immunogenetics of lithium response and psychiatric phenotypes in patients with bipolar disorder. *Transl Psychiatry*. 2024;14(1):174. <https://doi.org/10.1038/s41398-024-02865-4>
- Hou L, Heilbronner U, Degenhardt F, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. *Lancet*. 2016;387(10023):1085–93. [https://doi.org/10.1016/S0140-6736\(16\)00143-4](https://doi.org/10.1016/S0140-6736(16)00143-4).
- Lambert SA, Gil L, Jupp S, et al. The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. *Nat Genet*. 2021;53(4):420–5. <https://doi.org/10.1038/s41588-021-00783-5>.
- Ma Y, Patil S, Zhou X, Mukherjee B, Fritsche LG. ExPRSweb: an online repository with polygenic risk scores for common health-related exposures. *Am J Hum Genet*. 2022;109(10):1742–60. <https://doi.org/10.1016/j.ajhg.2022.09.001>.
- Manchia M, Adli M, Akula N, et al. Assessment of response to lithium maintenance treatment in bipolar disorder: a consortium on lithium genetics (ConLiGen) report. *PLoS ONE*. 2013;8(6):e65636. <https://doi.org/10.1371/journal.pone.0065636>.
- Miller BJ, McCall WV. Insomnia and suicide as reported adverse effects of second-generation antipsychotics and mood stabilizers. *J Clin Sleep Med*. 2022;18(2):517–22. <https://doi.org/10.5664/jcsm.9646>.
- Nunes A, Ardaou R, Berghöfer A, et al. Prediction of lithium response using clinical data. *Acta Psychiatr Scand*. 2020;141(2):131–41. <https://doi.org/10.1111/acps.13122>.
- Papiol S, Schulze TG, Heilbronner U. Lithium response in bipolar disorder: Genetics, genomics, and beyond. *Neurosci Lett*. 2022;785:136786. <https://doi.org/10.1016/j.neulet.2022.136786>.
- Privé F, Aschard H, Carmi S, et al. Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort. *Am J Hum Genet*. 2022;109(1):12–23. <https://doi.org/10.1016/j.ajhg.2021.11.008>.
- Queissner R, Lenger M, Birner A, et al. The association between anti-inflammatory effects of long-term lithium treatment and illness course in Bipolar Disorder. *J Affect Disord*. 2021;281:228–34. <https://doi.org/10.1016/j.jad.2020.11.063>.
- Rybakowski JK. Antiviral, immunomodulatory, and neuroprotective effect of lithium. *J Integr Neurosci*. 2022;21(2):68. <https://doi.org/10.31083/jjin2102068>.
- Schubert KO, Thalamuthu A, Amare AT, et al. Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. *Transl Psychiatry*. 2021;11(1):606. <https://doi.org/10.1038/s41398-021-01702-2>.

- Steardo L Jr, de Filippis R, Carbone EA, Segura-Garcia C, Verkhatsky A, De Fazio P. Sleep disturbance in bipolar disorder: neuroglia and circadian rhythms. *Front Psychiatry*. 2019;10:501. <https://doi.org/10.3389/fpsy.2019.00501>.
- Sylvia LG, Shelton RC, Kemp DE, et al. Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). *Bipolar Disord*. 2015;17(2):212–23. <https://doi.org/10.1111/bdi.12243>.
- Szałach ŁP, Lisowska KA, Cudała WJ, Barbuti M, Perugi G. The immunomodulatory effect of lithium as a mechanism of action in bipolar disorder. *Front Neurosci*. 2023;17:1213766. <https://doi.org/10.3389/fnins.2023.1213766>.
- Tang J, Chen X, Xu X, et al. Significant linkage and association between a functional (GT)_n polymorphism in promoter of the N-methyl-D-aspartate receptor subunit gene (GRIN2A) and schizophrenia. *Neurosci Lett*. 2006;409(1):80–2. <https://doi.org/10.1016/j.neulet.2006.09.022>.
- Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. *Br J Psychiatry*. 2001;178(Suppl 41):S184–90.
- Vijayakumar A, Mahapatra NR. Renalase: a novel regulator of cardiometabolic and renal diseases. *Hypertens Res*. 2022;45(10):1582–98. <https://doi.org/10.1038/s41440-022-00986-1>.
- Volkman C, Bschor T, Köhler S. Lithium treatment over the lifespan in bipolar disorders. *Front Psychiatry*. 2020;11:377. <https://doi.org/10.3389/fpsy.2020.00377>.
- Xu N, Shinohara K, Saunders KEA, Geddes JR, Cipriani A. Effect of lithium on circadian rhythm in bipolar disorder: A systematic review and meta-analysis. *Bipolar Disord*. 2021;23(5):445–53. <https://doi.org/10.1111/bdi.13070>.
- Yoshida T, Papiol S, Plans L, et al. The polygenic effect of the response to lithium on suicidal behavior. *Eur Neuropsychopharmacol*. 2019;29:S179. <https://doi.org/10.1016/j.euroneuro.2019.08.124>.
- Yu Z, Ono C, Aiba S, et al. Therapeutic concentration of lithium stimulates complement C3 production in dendritic cells and microglia via GSK-3 inhibition. *Glia*. 2015;63(2):257–70. <https://doi.org/10.1002/glia.22749>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.